期刊
CANCER LETTERS
卷 346, 期 1, 页码 84-93出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2013.12.016
关键词
Histone deacetylase inhibitor; Cisplatin; Apoptosis; Metastasis; Non-small cell lung cancer
类别
资金
- National Science Council, Taiwan [NSC102-2325-B-400-010, NSC102-2325-B-006-008]
Many histone deacetylase (HDAC) inhibitors show limited therapeutic effects for solid tumors. Here, we develop a novel HDAC inhibitor YCW1 and verify the combination effect of YCW1 and cisplatin in lung cancer pre-clinical models. YCW1 exerted cancer-specific cytotoxicity via mitochondria-mediated apoptosis. YCW1 and cisplatin showed synergistic anti-tumor effects through impairment of DNA damage repair. YCW1 inhibited tumor growth in lung orthotopic and subcutaneously implanted xenograft models. YCW1 significantly suppressed lung metastases via inhibition of focal adhesion complex. Our findings suggested that YCW1 is a potential HDAC inhibitor for lung cancer treatment as single and in combination regimens with cisplatin. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据